Literature DB >> 17415652

Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia.

Supriya Joshi1, Magdalena Kuczynski, E Jenny Heathcote.   

Abstract

Mixed cryoglobulins are detected in 50% of patients with hepatitis C; fortunately, few have vasculitis affecting skin, peripheral nerves, kidneys, and synovia. This study was designed to identify the natural history of symptomatic cryoglobulinemia and evaluate the response to antiviral therapy. Patients with hepatitis C complicated by symptomatic cryoglobulinemia were assessed for their disease manifestations and response to antiviral therapy. Of 83 patients identified, 56 patients with a minimum of 12 months follow-up were reviewed. Manifestations included dermatologic (75%), rheumatologic (57%), neurologic (34%), and renal (proteinuria 25%). Antiviral therapy was given to 38, of whom 9 were retreated for symptomatic and/or virological nonresponse. Antiviral therapy included interferon monotherapy (n= 8), pegylated-interferon monotherapy (n= 5), consensus-interferon (n= 2), interferon + ribavirin (n= 18), and pegylated-interferon + ribavirin (n= 14). Treatment provided sustained symptomatic response in 31 (82%) and virological response in 16 (42%) patients. Symptomatic cryoglobulinemia responds well to antiviral therapy, even when virological response is not achieved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17415652     DOI: 10.1007/s10620-006-9355-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  22 in total

1.  Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha.

Authors:  E Zuckerman; D Keren; G Slobodin; I Rosner; M Rozenbaum; E Toubi; E Sabo; I Tsykounov; J E Naschitz; D Yeshurun
Journal:  J Rheumatol       Date:  2000-09       Impact factor: 4.666

2.  Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia.

Authors:  C Donada; A Crucitti; V Donadon; L Chemello; A Alberti
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

3.  Cyclophosphamide therapy in a patient with membranoproliferative glomerulonephritis and essential mixed cryoglobulinaemia.

Authors:  M Abu-Shakra; M J Hausmann; L Kachko; D Flusser; D Buskila; S Sukenik
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 4.  Hepatitis C virus infection and cryoglobulinemia.

Authors:  F Lunel; L Musset
Journal:  J Hepatol       Date:  1998-11       Impact factor: 25.083

5.  Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.

Authors:  Patrice Cacoub; Olivier Lidove; Thierry Maisonobe; Pierre Duhaut; Vincent Thibault; Pascale Ghillani; Robert P Myers; Jean Marc Leger; Jérôme Servan; Jean-Charles Piette
Journal:  Arthritis Rheum       Date:  2002-12

6.  Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis.

Authors:  Zeid Kayali; Victor E Buckwold; Bridget Zimmerman; Warren N Schmidt
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

7.  Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.

Authors:  Cesare Mazzaro; Francesca Zorat; Manuela Caizzi; Carlo Donada; Giampiero Di Gennaro; Luigino Dal Maso; Giorgio Carniello; Luigi Virgolini; Umberto Tirelli; Gabriele Pozzato
Journal:  J Hepatol       Date:  2005-05       Impact factor: 25.083

8.  PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.

Authors:  Patrice Cacoub; David Saadoun; Nicolas Limal; Damien Sene; Olivier Lidove; Jean-Charles Piette
Journal:  Arthritis Rheum       Date:  2005-03

9.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

10.  Ribavirin in hepatitis C related cryoglobulinemia.

Authors:  J M Durand; P Cacoub; F Lunel-Fabiani; J Cosserat; E Cretel; G Kaplanski; C Frances; O Bletry; J Soubeyrand; P Godeau
Journal:  J Rheumatol       Date:  1998-06       Impact factor: 4.666

View more
  3 in total

Review 1.  HCV Treatments and Their Integration Into Rheumatology.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Curr Rheumatol Rep       Date:  2015-08       Impact factor: 4.592

Review 2.  Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.686

3.  Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study.

Authors:  Gianfranco Lauletta; Sabino Russi; Vincenza Conteduca; Loredana Sansonno; Franco Dammacco; Domenico Sansonno
Journal:  Medicine (Baltimore)       Date:  2013-09       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.